Efficacy of bivalent CEACAM6/4-1BBL genetic vaccine combined with anti-PD1 antibody in MC38 tumor model of mice
We used mouse CRC cell line (MC38) to establish a heterotopic mouse model, and applied [89Zr]-labeled PD-L1 antibody KN035 for PET imaging. Attenuated Salmonella typhimurium 3261 was used as an anti-tumor vaccine, and the combined anti-tumor immunotherapy with bivalent genetic vaccine and anti-PD1 a...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-10-01
|
| Series: | Heliyon |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844022020631 |
| _version_ | 1811192572474818560 |
|---|---|
| author | Yuzhen Li Xiaodan Zhu Jianliang You Baonan Zhang Xiaona Huang Chunhui Jin |
| author_facet | Yuzhen Li Xiaodan Zhu Jianliang You Baonan Zhang Xiaona Huang Chunhui Jin |
| author_sort | Yuzhen Li |
| collection | DOAJ |
| description | We used mouse CRC cell line (MC38) to establish a heterotopic mouse model, and applied [89Zr]-labeled PD-L1 antibody KN035 for PET imaging. Attenuated Salmonella typhimurium 3261 was used as an anti-tumor vaccine, and the combined anti-tumor immunotherapy with bivalent genetic vaccine and anti-PD1 antibody Nivolumab was conducted. MicroPET was performed to observe the changes of tumor tissues and expression of PD-L1. We found that the recombinant double-gene plasmids were stably expressed in COS7 cells. Study results showed the combined immunotherapy improved the effectiveness over genetic vaccine alone. This study supports that combination of genetic vaccines and anti-immunocheckpoint immunotherapy can inhibit MC38 tumor growth. |
| first_indexed | 2024-04-11T23:54:50Z |
| format | Article |
| id | doaj.art-126a74a7b0f145d4901e629880279254 |
| institution | Directory Open Access Journal |
| issn | 2405-8440 |
| language | English |
| last_indexed | 2024-04-11T23:54:50Z |
| publishDate | 2022-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Heliyon |
| spelling | doaj.art-126a74a7b0f145d4901e6298802792542022-12-22T03:56:23ZengElsevierHeliyon2405-84402022-10-01810e10775Efficacy of bivalent CEACAM6/4-1BBL genetic vaccine combined with anti-PD1 antibody in MC38 tumor model of miceYuzhen Li0Xiaodan Zhu1Jianliang You2Baonan Zhang3Xiaona Huang4Chunhui Jin5Department of Oncology, Wuxi Hospital Affiliated to Nanjing University of Chinese Medicine, Wuxi, ChinaDepartment of Oncology, Wuxi Hospital Affiliated to Nanjing University of Chinese Medicine, Wuxi, ChinaDepartment of Oncology, Wuxi Hospital Affiliated to Nanjing University of Chinese Medicine, Wuxi, ChinaDepartment of Oncology, Wuxi Hospital Affiliated to Nanjing University of Chinese Medicine, Wuxi, ChinaDepartment of Oncology, Wuxi Hospital Affiliated to Nanjing University of Chinese Medicine, Wuxi, ChinaCorresponding author.; Department of Oncology, Wuxi Hospital Affiliated to Nanjing University of Chinese Medicine, Wuxi, ChinaWe used mouse CRC cell line (MC38) to establish a heterotopic mouse model, and applied [89Zr]-labeled PD-L1 antibody KN035 for PET imaging. Attenuated Salmonella typhimurium 3261 was used as an anti-tumor vaccine, and the combined anti-tumor immunotherapy with bivalent genetic vaccine and anti-PD1 antibody Nivolumab was conducted. MicroPET was performed to observe the changes of tumor tissues and expression of PD-L1. We found that the recombinant double-gene plasmids were stably expressed in COS7 cells. Study results showed the combined immunotherapy improved the effectiveness over genetic vaccine alone. This study supports that combination of genetic vaccines and anti-immunocheckpoint immunotherapy can inhibit MC38 tumor growth.http://www.sciencedirect.com/science/article/pii/S2405844022020631Colorectal cancerAnti-tumor immunotherapyGenetic vaccineCEACAM64-1BBLAnti-PD1 drug |
| spellingShingle | Yuzhen Li Xiaodan Zhu Jianliang You Baonan Zhang Xiaona Huang Chunhui Jin Efficacy of bivalent CEACAM6/4-1BBL genetic vaccine combined with anti-PD1 antibody in MC38 tumor model of mice Heliyon Colorectal cancer Anti-tumor immunotherapy Genetic vaccine CEACAM6 4-1BBL Anti-PD1 drug |
| title | Efficacy of bivalent CEACAM6/4-1BBL genetic vaccine combined with anti-PD1 antibody in MC38 tumor model of mice |
| title_full | Efficacy of bivalent CEACAM6/4-1BBL genetic vaccine combined with anti-PD1 antibody in MC38 tumor model of mice |
| title_fullStr | Efficacy of bivalent CEACAM6/4-1BBL genetic vaccine combined with anti-PD1 antibody in MC38 tumor model of mice |
| title_full_unstemmed | Efficacy of bivalent CEACAM6/4-1BBL genetic vaccine combined with anti-PD1 antibody in MC38 tumor model of mice |
| title_short | Efficacy of bivalent CEACAM6/4-1BBL genetic vaccine combined with anti-PD1 antibody in MC38 tumor model of mice |
| title_sort | efficacy of bivalent ceacam6 4 1bbl genetic vaccine combined with anti pd1 antibody in mc38 tumor model of mice |
| topic | Colorectal cancer Anti-tumor immunotherapy Genetic vaccine CEACAM6 4-1BBL Anti-PD1 drug |
| url | http://www.sciencedirect.com/science/article/pii/S2405844022020631 |
| work_keys_str_mv | AT yuzhenli efficacyofbivalentceacam641bblgeneticvaccinecombinedwithantipd1antibodyinmc38tumormodelofmice AT xiaodanzhu efficacyofbivalentceacam641bblgeneticvaccinecombinedwithantipd1antibodyinmc38tumormodelofmice AT jianliangyou efficacyofbivalentceacam641bblgeneticvaccinecombinedwithantipd1antibodyinmc38tumormodelofmice AT baonanzhang efficacyofbivalentceacam641bblgeneticvaccinecombinedwithantipd1antibodyinmc38tumormodelofmice AT xiaonahuang efficacyofbivalentceacam641bblgeneticvaccinecombinedwithantipd1antibodyinmc38tumormodelofmice AT chunhuijin efficacyofbivalentceacam641bblgeneticvaccinecombinedwithantipd1antibodyinmc38tumormodelofmice |